Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy

NCT01755767 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT01755767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01755767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Lead sponsor
Daiichi Sankyo
Phase
Phase 3
Overall status
Completed
Start date
December 27, 2012
Completion date
July 31, 2017
Enrollment
383 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma